Three unprofitable healthcare companies went public this past week, out of a potential eight IPOs. These included a large biotech targeting rare diseases, a medical device maker, and a synthetic DNA company. The group raised $390 million and averaged a...read more
Axonics Modulation Technologies, which is commercializing a neural implant for overactive bladder and incontinence, raised $120 million by offering 8 million shares at $15, the midpoint of the $14 to $16 range. Axonics previously filed to offer 6.7 million...read more
As many as 7 IPOs could raise about $450 million in the week ahead, including 6 healthcare deals. Don't expect all of them to get done. IPOs have sold off alongside the broader markets, while the VIX Volatility Index is in the "IPO postponement zone." read more
Axonics Modulation Technologies, which is commercializing a neural implant for overactive bladder and incontinence, announced terms for its IPO on Monday. The Irvine, CA-based company plans to raise $100 million by offering 6.7 million shares at a price...read more
US IPO Weekly Recap: 3 healthcare IPOs trade flat
Three unprofitable healthcare companies went public this past week, out of a potential eight IPOs. These included a large biotech targeting rare diseases, a medical device maker, and a synthetic DNA company. The group raised $390 million and averaged a...read more
Shocking debut: Overactive bladder implant Axonics Modulation prices upsized $120 million IPO at $15 midpoint
Axonics Modulation Technologies, which is commercializing a neural implant for overactive bladder and incontinence, raised $120 million by offering 8 million shares at $15, the midpoint of the $14 to $16 range. Axonics previously filed to offer 6.7 million...read more
US IPO Week Ahead: Micro-cap healthcare dominates week with up to 7 IPOs
As many as 7 IPOs could raise about $450 million in the week ahead, including 6 healthcare deals. Don't expect all of them to get done. IPOs have sold off alongside the broader markets, while the VIX Volatility Index is in the "IPO postponement zone."read more
Early-stage device maker Axonics Modulation Technologies sets terms for $100 million IPO
Axonics Modulation Technologies, which is commercializing a neural implant for overactive bladder and incontinence, announced terms for its IPO on Monday. The Irvine, CA-based company plans to raise $100 million by offering 6.7 million shares at a price...read more